Talk:Monoamine releasing agent

This is the talk page for discussing improvements to the Monoamine releasing agent article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

This article has not yet been rated on Wikipedia's content assessment scale.
It is of interest to the following WikiProjects:

Please add the quality rating to the {{WikiProject banner shell}} template instead of this project banner. See WP:PIQA for details.

Pharmacology Start‑class Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Start	This article has been rated as Start-class on Wikipedia's content assessment scale.
Mid	This article has been rated as Mid-importance on the project's importance scale.

Please add the quality rating to the {{WikiProject banner shell}} template instead of this project banner. See WP:PIQA for details.

Neuroscience Start‑class Low‑importance

	This article is within the scope of WikiProject Neuroscience, a collaborative effort to improve the coverage of Neuroscience on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.NeuroscienceWikipedia:WikiProject NeuroscienceTemplate:WikiProject Neuroscienceneuroscience articles
Start	This article has been rated as Start-class on Wikipedia's content assessment scale.
Low	This article has been rated as Low-importance on the project's importance scale.

Please add the quality rating to the {{WikiProject banner shell}} template instead of this project banner. See WP:PIQA for details.

Molecular Biology: MCB Start‑class

	This article is within the scope of WikiProject Molecular Biology, a collaborative effort to improve the coverage of Molecular Biology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.Molecular BiologyWikipedia:WikiProject Molecular BiologyTemplate:WikiProject Molecular BiologyMolecular Biology articles
Start	This article has been rated as Start-class on Wikipedia's content assessment scale.
???	This article has not yet received a rating on the importance scale.
	This article is supported by the Molecular and Cell Biology task force (assessed as Low-importance).

Please add the quality rating to the {{WikiProject banner shell}} template instead of this project banner. See WP:PIQA for details.

Medicine Start‑class Low‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Start	This article has been rated as Start-class on Wikipedia's content assessment scale.
Low	This article has been rated as Low-importance on the project's importance scale.

Mechanism

@Petergstrom: What I deleted in this edit is not "new research" which contrasts with what is written there. It's describing a downstream effect of TAAR1 agonism: the phosphorylation of a monoamine transporter by PKC which induces the directional reversal of monoamine transport through a plasma membrane monoamine transporter (i.e., DAT, NET, or SERT). TAAR1 activates the PKC phosphorylation cascade.

The disruption of the pH gradient that was mentioned is a specific hypothesis about how these drugs induce monoamine release from vesicular stores through VMAT2, but not necessarily inhibit reuptake through VMAT2 (e.g., amphetamine and methamphetamine respectively displace tetrabenazine and reserpine from their respective binding sites on VMAT2 - those drugs are VMAT2 reuptake inhibitors that do not induce efflux through VMAT2). While I believe that the hypothesis is likely correct, I'd wait until it is verified before covering it as an actual mechanism of monoamine release. For now, I think it's sufficient to simply say that these drugs inhibit VMAT2 reuptake and induce monoamine release through VMAT2. Seppi333 (Insert 2¢) 21:53, 6 January 2017 (UTC)[reply]

"noradrenergic drugs (like) ephedrine (...) trend towards liking"

I'm curious as to what in the linked source justifies the claim that selective norepinephrine releasing agents are rewarding and/or recreational by any stretch of the meanings. Ephedrine is not a selective NRA, its selectivity for inducing NE release over DA can be as low as 5,5 to 1, which is nowhere near what's considered selective. A singular pilot study done on non-drug users about an MRA drug not selective for norepinephrine doesn't prove the outlandish claim that "noradrenergic drugs" are rewarding. Suggesting that said "noradrenergic drugs" are rewarding is also contradicting the well-documented aversive CNS effects of selective norepinephrine reuptake inhibitors and direct adrenergic agonists.

My guess is that a misunderstanding that phenylpropanolamines are selective NRAs somehow exists because those drugs are often considered selective sympathomimetics, which has nothing to do with actual selectivity for NE release and everything to do with low blood-brain barrier penetration relative to amphetamine and methamphetamine. Reph-415 (talk) 17:40, 12 August 2023 (UTC)[reply]